Back

Executive Coffee Chat with Jan Elias Hansen, VP of Evidence for Access at Genentech

Virtual  
Monday, June 13, 2022 9:00 AM - 10:00 AM   Add to Calendar Pacific Standard Time

Jan Hansen, PhD, is Vice President of the Evidence for Access Unit within Genentech’s US Medical Affairs organization. Her unit is staffed with health economists, outcomes researchers, and health services researchers who are uniquely positioned and skilled to address the value, quality and policy drivers associated with access to health care in the US. These scientists are tasked to consider impacts on value, quality, systems, and policies when developing research strategies and tactics. . Jan is a seasoned executive with more than thirty years of experience in the health care, life sciences and pharmaceutical industries. Jan’s pharmacoeconomics and health outcomes expertise has been acquired and applied throughout her career across a vast set of areas including: patient-based research, health care consulting, sales strategy and execution, strategic planning, organizational design and development, and outcomes research (global and US roles). In addition to Genentech (a member of the Roche Group) she has held positions with increasing leadership responsibility at several well-regarded companies, including PCS-Pharmaceutical Data Services (now CVS-Caremark), NDC Health/Wolters Kluwer Health (now Symphony Health), Glaxo Wellcome (now GlaxoSmithkline), and Allergan (now part of AbbVie). . Her professional accomplishments have been recognized by several professional organizations and resulted in numerous appointments, including: the University of Iowa College of Pharmacy Advisory Council, past Chair and current member of the University of Washington College of Pharmacy’s Corporate Advisory Council, Board member (representing Genentech) of the National Pharmaceutical Council (NPC), past Board member of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), past member of the Drug Information Association (DIA) Advisory Council of North America, past NPC Corresponding Officer and Research Committee member (representing Allergan), member of the Academy Health Corporate Council, Center for Evaluation of Value and Risk (CEVR) Life Sciences Advisory Board, PhRMA Foundation Value Assessment Advisory Committee, and past Academy of Managed Care Pharmacy (AMCP) Foundation Board of Trustee, to name a few. . Jan is a licensed pharmacist and holds a Ph.D. in Pharmacy Administration from the University of South Carolina at Columbia. She is also a speaker and guest lecturer on topics related to pharmacoeconomics and outcomes research. . Jan’s ultimate passion is “building”; she takes great pride in building organizations and fostering young, innovative-thinking, yet applied, researchers. As a leader of health economics and health services/outcomes professionals, she is committed to the appropriate training, mentoring and development of the next generation of researchers, and thrives on the application of health economic, outcomes, and health services research. For Jan, there is no greater joy than watching these researchers flourish and making a difference in to health care decision making, and ultimately, to patients’ lives.

The meeting is full and there is no waitlist available

HBA San Francisco Bay Area presents

Executive Coffee Chat with Jan Elias Hansen, VP of Evidence for Access at Genentech

Date and time
Monday, 13 June
09:00AM - 10:00AM PST
Location
Virtual

Event Contact
Saba Nikpour
+1 (732) 485-7430
Competencies
9. Networks and ethically self-promotes

Jan Hansen, PhD, is Vice President of the Evidence for Access Unit within Genentech’s US Medical Affairs organization. Her unit is staffed with health economists, outcomes researchers, and health services researchers who are uniquely positioned and skilled to address the value, quality and policy drivers associated with access to health care in the US. These scientists are tasked to consider impacts on value, quality, systems, and policies when developing research strategies and tactics.
.
Jan is a seasoned executive with more than thirty years of experience in the health care, life sciences and pharmaceutical industries. Jan’s pharmacoeconomics and health outcomes expertise has been acquired and applied throughout her career across a vast set of areas including: patient-based research, health care consulting, sales strategy and execution, strategic planning, organizational design and development, and outcomes research (global and US roles). In addition to Genentech (a member of the Roche Group) she has held positions with increasing leadership responsibility at several well-regarded companies, including PCS-Pharmaceutical Data Services (now CVS-Caremark), NDC Health/Wolters Kluwer Health (now Symphony Health), Glaxo Wellcome (now GlaxoSmithkline), and Allergan (now part of AbbVie).
.
Her professional accomplishments have been recognized by several professional organizations and resulted in numerous appointments, including: the University of Iowa College of Pharmacy Advisory Council, past Chair and current member of the University of Washington College of Pharmacy’s Corporate Advisory Council, Board member (representing Genentech) of the National Pharmaceutical Council (NPC), past Board member of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), past member of the Drug Information Association (DIA) Advisory Council of North America, past NPC Corresponding Officer and Research Committee member (representing Allergan), member of the Academy Health Corporate Council, Center for Evaluation of Value and Risk (CEVR) Life Sciences Advisory Board, PhRMA Foundation Value Assessment Advisory Committee, and past Academy of Managed Care Pharmacy (AMCP) Foundation Board of Trustee, to name a few.
.
Jan is a licensed pharmacist and holds a Ph.D. in Pharmacy Administration from the University of South Carolina at Columbia. She is also a speaker and guest lecturer on topics related to pharmacoeconomics and outcomes research.
.
Jan’s ultimate passion is “building”; she takes great pride in building organizations and fostering young, innovative-thinking, yet applied, researchers. As a leader of health economics and health services/outcomes professionals, she is committed to the appropriate training, mentoring and development of the next generation of researchers, and thrives on the application of health economic, outcomes, and health services research. For Jan, there is no greater joy than watching these researchers flourish and making a difference in to health care decision making, and ultimately, to patients’ lives.

Registration information
Event is open to: HBA Members only

Registration information

The registration button at the bottom of the page will not show if online registration has closed or if the event has reached capacity. If you are a guest and the registration button is not showing, it may be that this is a member-only event. Read more about the benefits of membership or contact us about membership.

The HBA will make reasonable modifications to policies and programs to ensure that people with special needs have an equal opportunity to enjoy all of its programs. Contact us if you require special accommodations for this event.

 Price LevelRegular
Collapse group

Registration: Regular Registration
 Member$0.00
 Member - Euro€0.00
The meeting is full and there is no waitlist available

By registering for this event, you acknowledge that you may be photographed, videotaped and/or audio-taped during the course of the meeting and hereby give permission for your image, voice, or survey comments to be used in education, training, promotion and/or trade and communications media by the Healthcare Businesswomen's Association in any and all media throughout the world, without restriction as to frequency or duration of usage.